We pioneered studies using low doses of PMZ-2010, which significantly reduced the mortality, decreased blood lactate, and increased mean arterial pressure, pulse pressure and cardiac output in hemorrhagic shock.
We have carried out comparative studies between PMZ-2010 and status quo resuscitative agents grouped into 3 different categories: (a) fluids such as Lactated Ringer’s, hypertonic saline; (b) adrenergic agents such as norepinephrine; and (c) fresh blood. Our results using (i) a rat model of fixed pressure blood loss, (ii) a rabbit model of uncontrolled bleeding with trauma, and (iii) a pig model of massive blood loss, indicate that PMZ-2010 is highly effective in reducing the mortality following hypovolemic shock.
PMZ-2010 acts through a unique mechanism of action that is completely different from any of the existing drugs or investigational products. It is NOT a vasopressor, however, it increases blood pressure and cardiac output by augmenting venous blood return to the heart (alpha2B-adrenergic stimulation), and it enhances tissue perfusion by arterial dilatation (alpha1-adrenergic block). Enhancing tissue perfusion is a significant advantage in reducing the adverse effects of existing vasopressors. Moreover, it does not act on beta-adrenergic receptors, and therefore the risk of arrhythmias is mitigated.
Patents issued in Australia, Japan, India, China and European Union.
Clinical stage – Phase I (CTRI/2014/06/004647) completed; Phase II (CTRI/2017/03/008184) completed; Phase III (CTRI/2019/01/017196) ongoing.
Hypovolemic Shock (PMZ-2010)